First patients were treated in May 2020. Topline results are anticipated on the three-month primary endpoint and six-month follow-up period in 3Q21.
The controlled, randomized, double-blind trial is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce OA pain in the knee up to 12 months, compared to placebo or Hylan G-F 20 (Synvisc).
JTA-004 is a blend of hyaluronic acid and a fast-acting analgesic intended to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a previous randomized, double-blind Phase II study involving 164 patients, JTA-004 showed superior clinical benefit with an improved pain relief at three and six months compared to Hylan G-F 20.
“The Covid-19 pandemic has had a substantial impact on the progress of clinical studies globally. As a result, Bone Therapeutics successfully completing patient recruitment of this large clinical study, evaluating more than 700 patients, on time and schedule, is a tremendous achievement. The contribution of patients, clinicians, clinical study operators has been invaluable to achieving this major milestone.” – Olivier Godeaux, Chief Medical Officer of Bone Therapeutics
First patients were treated in May 2020. Topline results are anticipated on the three-month primary endpoint and six-month follow-up period in 3Q21.
The controlled, randomized, double-blind trial is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce OA pain in the knee up to 12 months, compared to placebo or Hylan G-F 20 (Synvisc).
JTA-004 is a blend of hyaluronic acid and a fast-acting analgesic intended to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a previous randomized, double-blind Phase II study involving 164 patients, JTA-004 showed superior clinical benefit with an improved pain relief at three and six months compared to Hylan G-F 20.
“The Covid-19 pandemic has had a substantial impact on the progress of clinical studies globally. As a result, Bone Therapeutics successfully completing patient recruitment of this large clinical study, evaluating more than 700 patients, on time and schedule, is a tremendous achievement. The contribution of patients, clinicians, clinical study operators has been invaluable to achieving this major milestone.” – Olivier Godeaux, Chief Medical Officer of Bone Therapeutics
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
